Bioventus (BVS) Competitors

National Vision (NASDAQ:EYE) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Is EYE or BVS more profitable?

Bioventus has a net margin of -0.03% compared to National Vision's net margin of -0.75%. Bioventus' return on equity of 23.04% beat National Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Vision	-0.75%	3.56%	1.49%
Bioventus	-0.03%	23.04%	6.04%

Do insiders and institutionals have more ownership in EYE or BVS?

62.9% of Bioventus shares are held by institutional investors. 2.7% of National Vision shares are held by insiders. Comparatively, 33.0% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media favor EYE or BVS?

In the previous week, National Vision had 2 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for National Vision and 1 mentions for Bioventus. National Vision's average media sentiment score of 1.03 beat Bioventus' score of 0.00 indicating that National Vision is being referred to more favorably in the media.

Company	Overall Sentiment
National Vision	Positive
Bioventus	Neutral

Which has better valuation and earnings, EYE or BVS?

National Vision has higher revenue and earnings than Bioventus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Vision	$1.82B	1.20	-$28.50M	-$0.18	-153.00
Bioventus	$573.28M	0.97	-$33.54M	N/A	N/A

Do analysts rate EYE or BVS?

National Vision presently has a consensus price target of $24.73, suggesting a potential downside of 10.21%. Given National Vision's stronger consensus rating and higher probable upside, equities analysts plainly believe National Vision is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Vision	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Bioventus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Which has more volatility and risk, EYE or BVS?

National Vision has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Summary

National Vision beats Bioventus on 9 of the 15 factors compared between the two stocks.